]>
IRCT20210907052400N2 IRCT 2021-10-06 Hamedan University of Medical Sciences The effects of coenzyme Q10 on cerebral infarction CoQ10 Effects of oral administration of ubiquinone in cerebral stroke patients on the neurologic, psycho-cognitive and oxidative stress disorders 2021-10-12 anticipated 50 Complete https://irct.ir/trial/58721 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: n this study, a neurologist selects ischemic stroke patients according to inclusion and non-inclusion criteria and introduces them to researchers. After fully explaining the treatment process of this study to patients and obtaining written consent, the researchers enter the patients into the study. After conducting initial assessments, the evaluating researcher provides the physician and nurses with therapeutic intervention, including capsules containing CO Q10 powder and placebo capsules (containing glucose powder), to be placed in the patient's order. The capsules are exactly the same in appearance and packaging, and the medical staff will not be aware of their main contents. The leader researcher in this study is blind and only researchers evaluating and analyzing the data will be aware of the patient classification. 3 Ischemic stroke. Intervention 1: Intervention group: Half of the patients placed in the intervention group by the researcher; After initial evaluation of the initial variables and discharge from the hospital, they begin interventional therapy, which is complementary drug therapy with coenzyme Q10. In this study, patients will consume 600 mg of oral CoQ10 daily in the form of 200 mg capsules (3 servings per day) one hour before the main meals of breakfast, lunch and dinner for 30 days. The coenzyme Q10 oral powder used in this study; It is 98% pure and is made in South Korea. Intervention 2: Control group: The other half of the patients included in the study will be in the control group by the researcher of this study. All evaluations of patients in the intervention group will be performed at the beginning of the study and after discharge from the hospital, as in the first group, they will receive placebo capsules as complementary therapy; Take 3 servings of placebo capsules for 30 days. Patients who are blinded by the type of segmentation and the type of intervention; They receive a 200 mg capsule similar to the intervention capsules. The contents of the capsules of this group are filled with glucose powder. Yes - There is a plan to make this available What will be shared: In this study, only the results related to the study variables will be published When: Access starts 6 months after the results are published To whom: All people who are related to scientific and academic centers and industries related to health care can apply. Conditions: Only as a scientific source with the names of the authors are allowed to use the results. Where to obtain: Using e-mail addresses, they can contact the researchers of this study and the Vice Chancellor for Research and Technology of the University. Dr. Siamak Shahidi, shahidi@umsha.ac.ir Dr. Mojtaba, Khazaei, khazaeimojtaba@yahoo.com Ali Mojaver, a.mojaver.edu@umsha.ac.ir How to obtain: Applicants can send an email to the author responsible for the published articles. Request a copy of the article file. To be sent to them by e-mail. Comments:
public Mojtaba Khazaei
Be'sat hospital, Shahid Beheshti Blvd, Hamadan
Hamadan Iran (Islamic Republic of) 6516798798 +98 81 3565 0030 khazaeimojtaba@yahoo.com Hamedan University of Medical Sciences scientific Siamak Shahidi
Department of physiology, School of medicine, Hamadan University of medical sciences, Shahid Fahmide St, Hamedan
Hamadan Iran (Islamic Republic of) 6517838678 +98 81 3822 2104 shahidi@umsha.ac.ir Hamedan University of Medical Sciences Iran (Islamic Republic of) Patients with acute ischemic stroke Patients who have had a stroke for the first time Patients between the ages of 20 and 80 20 years 80 years Both Having other neurodegenerative disorders Having acute mental disorders Having liver and kidney malignancies Having rheumatism and chronic infections Taking vitamin supplements and immune boosters in the last month I63 Cerebral infarction Treatment - Drugs Treatment - Drugs Intervention group: Half of the patients placed in the intervention group by the researcher; After initial evaluation of the initial variables and discharge from the hospital, they begin interventional therapy, which is complementary drug therapy with coenzyme Q10. In this study, patients will consume 600 mg of oral CoQ10 daily in the form of 200 mg capsules (3 servings per day) one hour before the main meals of breakfast, lunch and dinner for 30 days. The coenzyme Q10 oral powder used in this study; It is 98% pure and is made in South Korea. Control group: The other half of the patients included in the study will be in the control group by the researcher of this study. All evaluations of patients in the intervention group will be performed at the beginning of the study and after discharge from the hospital, as in the first group, they will receive placebo capsules as complementary therapy; Take 3 servings of placebo capsules for 30 days. Patients who are blinded by the type of segmentation and the type of intervention; They receive a 200 mg capsule similar to the intervention capsules. The contents of the capsules of this group are filled with glucose powder. Oxidative stress. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Spectroscopy (by taking a blood sample). Sensory-motor function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using Berg Balance Scale. Psycho-cognitive function. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using the MoCA questionnaire. Physical activity rate. Timepoint: Immediately after the stroke event and before starting coenzyme Q10 treatment and then 30 days after consuming oral coenzyme Q10. Method of measurement: Using SIMPAQ questionnaire and Barthel index. Hamedan University of Medical Sciences Approved 2021-09-04 Ethics committee of Hamadan University of Medical Sciences Hamadan university of medical sciences, Shahid Fahmideh Blvd, Hamadan Hamadan Hamadan Iran (Islamic Republic of)